Literature DB >> 9878203

Novel alpha-synuclein-immunoreactive proteins in brain samples from the Contursi kindred, Parkinson's, and Alzheimer's disease.

J W Langston1, S Sastry, P Chan, L S Forno, L M Bolin, D A Di Monte.   

Abstract

A specific mutation (A53T) in the encoding region for alpha-synuclein has been identified in a large multigenerational family with an autosomal dominant parkinsonism known as the Contursi kindred. In this study, we used a monoclonal antibody directed against alpha-synuclein in order to identify novel proteins in the brain of an affected member of this kindred who had come to autopsy. Homogenates from the frontal cortex and caudate nucleus were examined using Western blot techniques and compared to matched autopsy specimens from control subjects and patients with various forms of parkinsonism. Western blots, using a 15-min exposure time, revealed the expected 19-kDa band representing alpha-synuclein in all brain samples examined. However, a novel band in the 36-kDa range was also present in the Contursi brain which was not seen in cortex or caudate from control brains or in frontal cortex from 14 cases of typical Parkinson's disease. With a 24-h exposure time, this band was faintly seen in the caudate nucleus of three of the Parkinson's disease cases. Surprisingly, the 36-kDa band (as well as other high-molecular-weight bands) was also present in frontal cortex and caudate nucleus in 3 additional cases that met diagnostic criteria for both Parkinson's disease and Alzheimer's disease. A preliminary analysis of samples from the frontal cortex of 10 Alzheimer's disease cases revealed a 36-kDa band in only one instance. The identification of novel alpha-synuclein-immunoreactive bands in these various forms of parkinsonism may open new research avenues for exploring the relationship between abnormal protein deposition in the brain and one or more neurodegenerative disorders, including the Contursi form of familial parkinsonism. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9878203     DOI: 10.1006/exnr.1998.6975

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  15 in total

1.  Multisystem Lewy body disease and the other parkinsonian disorders.

Authors:  J William Langston; Birgitt Schüle; Linda Rees; R Jeremy Nichols; Carrolee Barlow
Journal:  Nat Genet       Date:  2015-12       Impact factor: 38.330

2.  A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction.

Authors:  Andreas Puschmann; Owen A Ross; Carles Vilariño-Güell; Sarah J Lincoln; Jennifer M Kachergus; Stephanie A Cobb; Suzanne G Lindquist; Jørgen E Nielsen; Zbigniew K Wszolek; Matthew Farrer; Håkan Widner; Danielle van Westen; Douglas Hägerström; Katerina Markopoulou; Bruce A Chase; Karin Nilsson; Jan Reimer; Christer Nilsson
Journal:  Parkinsonism Relat Disord       Date:  2009-07-25       Impact factor: 4.891

3.  Cocaine abusers have an overexpression of alpha-synuclein in dopamine neurons.

Authors:  Deborah C Mash; Qinjie Ouyang; John Pablo; Margaret Basile; Sari Izenwasser; Abraham Lieberman; Richard J Perrin
Journal:  J Neurosci       Date:  2003-04-01       Impact factor: 6.167

Review 4.  Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.

Authors:  Orkid Coskuner-Weber; Vladimir N Uversky
Journal:  Int J Mol Sci       Date:  2018-01-24       Impact factor: 5.923

5.  Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice.

Authors:  Meike Diepenbroek; Nicolas Casadei; Hakan Esmer; Takaomi C Saido; Jiro Takano; Philipp J Kahle; Ralph A Nixon; Mala V Rao; Ronald Melki; Laura Pieri; Stefan Helling; Katrin Marcus; Rejko Krueger; Eliezer Masliah; Olaf Riess; Silke Nuber
Journal:  Hum Mol Genet       Date:  2014-03-11       Impact factor: 6.150

Review 6.  Diagnosis and treatment of Parkinson disease: molecules to medicine.

Authors:  Joseph M Savitt; Valina L Dawson; Ted M Dawson
Journal:  J Clin Invest       Date:  2006-07       Impact factor: 14.808

7.  Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson's disease. Variability in familial Parkinson's disease.

Authors:  K Markopoulou; D W Dickson; R D McComb; Z K Wszolek; L Katechalidou; L Avery; M S Stansbury; B A Chase
Journal:  Acta Neuropathol       Date:  2008-04-04       Impact factor: 17.088

Review 8.  The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia.

Authors:  Walter J Schulz-Schaeffer
Journal:  Acta Neuropathol       Date:  2010-06-20       Impact factor: 17.088

9.  Alpha-synuclein is expressed in different tissues during human fetal development.

Authors:  Svetlana Ltic; Milka Perovic; Aleksandra Mladenovic; Nevena Raicevic; Sabera Ruzdijic; Ljubisav Rakic; Selma Kanazir
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 10.  A53T in a parkinsonian family: a clinical update of the SNCA phenotypes.

Authors:  Nicola Tambasco; Pasquale Nigro; Michele Romoli; Paolo Prontera; Simone Simoni; Paolo Calabresi
Journal:  J Neural Transm (Vienna)       Date:  2016-06-01       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.